Chiasma

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

NeuroSense Therapeutics Ltd

OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--SpyBiotech has appointed Mark Leuchtenberger as its CEO. Sumi Biswas, the company's co-founder, remains President and a Director and becomes CSO.

SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

Amryt Pharma PLC

Amryt Pharma PLC has completed its acquisition of US group Chiasma Inc with Raj Kannan and Roni Mamluk joining the board as non-executive directors. Joe Wiley, Amryt's chief executive, said:  “This transaction further solidifies our position as a global leader in treating rare and orphan conditions.

Amryt Pharma completes Chiasma acquisition

Aerpio Pharmaceuticals Inc

Net Element

1Life Healthcare

Soliton

Sykes Enterprises

NEW YORK , July 10, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 1Life Healthcare, Inc. (NASDAQ: ONEM)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Iora Health. Under the terms of the merger, 1Life Healthcare will acquire Iora Health in an all-stock transaction.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm

Chiasma Inc (NASDAQ: CHMA) submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly. The application is supported by positive results from Phase 3 MPOWERED non-inferiority trial comparing Mycapssa to long-acting injectable somatostatin analogs (iSSAs).

Chiasma Files Mycapssa European Application For Acromegaly

Submission supported by previously announced data from Phase 3 MPOWERED™ study Submission supported by previously announced data from Phase 3 MPOWERED™ study

Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency

Chiasma Inc (NASDAQ: CHMA) has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone. Data demonstrated that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to Mycapssa.

Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients

--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- --Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®--

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society's 2021 annual meeting --

Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences

Acasti Pharma

Ferro

Domtar

NEW YORK, May 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Domtar Corporation (NYSE: UFS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Paper Excellence for $55.50 per share in cash. If you are a Domtar shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm

IRVING, Texas--(BUSINESS WIRE)--Acentrus Specialty™ has finalized an agreement with Chiasma, Inc. to provide qualified Acentrus clients access to MYCAPSSA® (octreotide).

Acentrus Specialty Contracts with Chiasma to Bring MYCAPSSA® (octreotide) to Health Systems and Hospitals in the Acentrus Network

Chiasma (CHMA) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Chiasma (CHMA) is Overbought: Is A Drop Coming?

Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)

NEW YORK, May 7, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Chiasma, Inc. ("CHMA" or the "Company") ( CHMA )  relating to its proposed acquisition by Amryt Pharma plc. Under the terms of the agreement, CHMA shareholders will receive 0.396 Amryt American Depositary Share, each representative of five Amryt ordinary shares, per share they own.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chiasma, Inc. - CHMA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chiasma, Inc. (NasdaqGS: CHMA) to Amryt (NasdaqGS: AMYT). Under the terms of the proposed transaction, shareholders of Chiasma will receive 0.396 American Depositary Shares of Amryt for each share of Chiasma that they own. KSF is seeking to determine whether this consideration and the process that led to it ar

CHIASMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chiasma, Inc. - CHMA

NEW YORK, May 5, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Chiasma, Inc. (NASDAQ: CHMA) and its board of directors concerning the proposed acquisition of the company by Amryt (NASDAQ: AMYT). Stockholders will receive 0.396 Amryt American Depository Shares for each share of Chiasma stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Chiasma, Inc.

NEW YORK, May 5, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Chiasma, Inc. ("Chiasma" or the "Company") (NASDAQ: CHMA) in connection with the proposed acquisition of the Company by Amryt Pharma plc ("Amryt") (NASDAQ: AMYT). Under the terms of the merger agreement, Chiasma stockholders will receive 0.396 Amryt American Depositary Shares ("ADSs"), each representing five Amryt ordinary shares, for each Chiasma share that they own, representing implied consideration of $5.13 based upon Amryt's ADS's May 4, 2021 closing price of $12.95.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Chiasma, Inc.

Chiasma (NASDAQ:CHMA) shares are trading higher after Amryt announces that it has signed a definitive agreement to acquire Chiasma in an all-stock combination. Chiasma is currently up 39.78% to a price of $3.96.

Why Chiasma's Stock Is Surging Today

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Chiasma, Inc. (NASDAQ: CHMA) to Amryt Pharma plc is fair to Chiasma shareholders. Under the terms of the agreement, each share of Chiasma common stock issued and outstanding prior to the consummation of the transaction will be exchanged for 0.396 Amryt American Depositary Shares, each representing five Amryt ordinary shares. Halper Sadeh encourages Chiasma shareholders to click h

Chiasma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Chiasma, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CHMA

Chiasma (CHMA) delivered earnings and revenue surprises of -63.33% and 6.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Chiasma (CHMA) Reports Q1 Loss, Tops Revenue Estimates

Amryt Pharma PLC (LON:AMYT NASDAQ:AMYT)  is to merge with fellow Nasdaq-listed biotech Chiasma Inc (NASDAQ:CHMA) through an all-share deal that will create a leading specialist in rare and orphan diseases. Chiasma's lead product is Mycapssa, the only orally-taken treatment approved in the US for the growth hormone imbalance condition acromegaly.

Amryt Pharma to merge with Chiasma and create rare diseases powerhouse

Ault Global Holdings

Farmmi

Penny stocks are making big waves on Cinco De Mayo; are these 3 worth watching? The post Hot Penny Stocks to Buy?

Hot Penny Stocks to Buy? 3 to Watch on Cinco De Mayo

The stock price of Chiasma Inc (NASDAQ: CHMA) increased from $2.84 to $4.07 (up 43.31%) pre-market. This is why it happened.

CHMA Stock: From $2.84 To $4.07 (43.31% Increase) Pre-Market Explanation

Amryt Pharma (NASDAQ: AMYT) has agreed to acquire Chiasma Inc (NASDAQ: CHMA) in an all-stock combination. Each Chiasma shares will be exchanged for 0.396 Amryt American Depositary Shares, each representing five Amryt ordinary shares.

Chiasma Stock Shoots Up On Amryt's All Stock Acquisition To Strengthen Position In Rare & Orphan Diseases

Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt

- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline

News for Chiasma Stock (CHMA)